Home
Search
Study Topics
Glossary
|
|
|
|
|
|
Sponsored by: |
National Institute of Allergy and Infectious Diseases (NIAID) |
---|---|
Information provided by: | National Institute of Allergy and Infectious Diseases (NIAID) |
ClinicalTrials.gov Identifier: | NCT00000796 |
To determine the demographic, behavioral, clinical, and geographic risk factors associated with the occurrence of multidrug-resistant pulmonary tuberculosis (MDRTB). To evaluate the clinical and microbiological responses and overall survival of MDRTB patients who are treated with levofloxacin-containing multiple-drug regimens chosen from a hierarchical list. Per 9/28/94 amendment, to assess whether persistent or recurrent positive sputum cultures of patients who show failure or relapse are due to the same strain or reinfection with a new strain.
Among TB patients, there has been an increase in progressive disease due to the emergence of antimycobacterial drug-resistant strains of Mycobacterium tuberculosis. Failure to identify patients at high risk for MDRTB increases the hazard for both treatment failure and development of resistance to additional therapeutic agents. Efforts to improve survival in patients with MDRTB will depend on improved methods of assessing the risk of acquisition of MDRTB and identifying drug susceptibility patterns in a timely fashion.
Condition | Intervention |
---|---|
HIV Infections Tuberculosis |
Drug: Cycloserine Drug: Ethionamide Drug: Capreomycin sulfate Drug: Aminosalicylic acid Drug: Streptomycin sulfate Drug: Ethambutol hydrochloride Drug: Amikacin sulfate Drug: Isoniazid Drug: Pyrazinamide Drug: Pyridoxine hydrochloride Drug: Levofloxacin Drug: Rifampin Drug: Clofazimine |
Study Type: | Interventional |
Study Design: | Treatment, Safety Study |
Official Title: | A Prospective Study of Multidrug Resistance and a Pilot Study of the Safety of and Clinical and Microbiologic Response to Levofloxacin in Combination With Other Antimycobacterial Drugs for Treatment of Multidrug-Resistant Pulmonary Tuberculosis (MDRTB) in HIV-Infected Patients. |
Estimated Enrollment: | 525 |
Among TB patients, there has been an increase in progressive disease due to the emergence of antimycobacterial drug-resistant strains of Mycobacterium tuberculosis. Failure to identify patients at high risk for MDRTB increases the hazard for both treatment failure and development of resistance to additional therapeutic agents. Efforts to improve survival in patients with MDRTB will depend on improved methods of assessing the risk of acquisition of MDRTB and identifying drug susceptibility patterns in a timely fashion.
Patients are asked a series of questions to determine epidemiologic factors that may be predictive of MDRTB. Patients who are determined to be at low risk for MDRTB will be referred to another TB treatment protocol (ACTG 222), if appropriate. Patients suspected of having primary or acquired MDRTB or those with confirmed MDRTB will be offered a regimen of anti-TB therapy from a hierarchically ordered list of drugs, based on the patient's resistance status (suspect primary MDRTB, suspect acquired MDRTB, or confirmed MDRTB). The hierarchical list is as follows: isoniazid, rifampin, ethambutol, streptomycin, levofloxacin, ethionamide, cycloserine, capreomycin, aminosalicylic acid, and clofazimine. Treatment will be administered daily for at least 6 months, then on an intermittent schedule at the clinician's discretion. Patients with confirmed MDRTB (defined as known resistance to at least isoniazid and rifampin within 6 months prior to study entry) will receive a minimum of 18 months of treatment following sputum culture conversion. Follow-up is performed every 4 weeks for 8 weeks, and then every 8 weeks.
Ages Eligible for Study: | 13 Years and older |
Genders Eligible for Study: | Both |
Accepts Healthy Volunteers: | No |
Inclusion Criteria
Patients must have:
Per 08/02/94 amendment, patients with confirmed MDRTB or known susceptibilities for the current episode at baseline are not eligible for the epidemiologic study only.
FOR TREATMENT PILOT:
Exclusion Criteria
Co-existing Condition:
Patients with the following symptoms or conditions are excluded:
Prior Medication:
Excluded:
United States, Illinois | |
Cook County Hosp | |
Chicago, Illinois, United States, 60612 | |
United States, Michigan | |
Henry Ford Hosp | |
Detroit, Michigan, United States, 48202 | |
United States, New York | |
Montefiore Drug Treatment Ctr / Bronx Municipal Hosp | |
Bronx, New York, United States, 10461 | |
Montefiore Family Health Ctr / Bronx Municipal Hosp | |
Bronx, New York, United States, 10461 | |
Samaritan Village Inc / Bronx Municipal Hosp | |
Bronx, New York, United States, 10461 | |
Bellevue Hosp / New York Univ Med Ctr | |
New York, New York, United States, 10016 | |
Mount Sinai Med Ctr | |
New York, New York, United States, 10029 | |
Jack Weiler Hosp / Bronx Municipal Hosp | |
Bronx, New York, United States, 10465 | |
Cornell Univ Med Ctr | |
New York, New York, United States, 10021 | |
Bronx Municipal Hosp Ctr/Jacobi Med Ctr | |
Bronx, New York, United States, 10461 | |
Interfaith Med Ctr | |
Brooklyn, New York, United States, 112032098 | |
Harlem AIDS Treatment Group / Harlem Hosp Ctr | |
New York, New York, United States, 10037 | |
Bronx Lebanon Hosp Ctr | |
Bronx, New York, United States, 10456 | |
Clinical Directors Network of Region II | |
New York, New York, United States, 10011 | |
Beth Israel Med Ctr | |
New York, New York, United States, 10003 | |
SUNY / Health Sciences Ctr at Brooklyn | |
Brooklyn, New York, United States, 112032098 | |
Saint Clare's Hosp and Health Ctr | |
New York, New York, United States, 10019 | |
North Central Bronx Hosp / Bronx Municipal Hosp | |
Bronx, New York, United States, 10467 | |
Comprehensive Health Care Ctr / Bronx Municipal Hosp | |
Bronx, New York, United States, 10461 | |
Columbia Presbyterian Med Ctr | |
New York, New York, United States, 100323784 | |
Montefiore Med Ctr / Bronx Municipal Hosp | |
Bronx, New York, United States, 10467 |
Study Chair: | Telzak E | |
Study Chair: | Benson C | |
Study Chair: | Chirgwin K | |
Study Chair: | Sepkowitz K |
Study ID Numbers: | ACTG 238, CPCRA 026 |
Study First Received: | November 2, 1999 |
Last Updated: | August 25, 2008 |
ClinicalTrials.gov Identifier: | NCT00000796 |
Health Authority: | United States: Federal Government |
Isoniazid Tuberculosis, Pulmonary Pyrazinamide Pyridoxine Ofloxacin Rifampin AIDS-Related Opportunistic Infections Drug Therapy, Combination Ethambutol Clofazimine |
Acquired Immunodeficiency Syndrome Amikacin Drug Resistance, Microbial Cycloserine Capreomycin Sulfate Ethionamide Aminosalicylic Acids Streptomycin p-Aminosalicylic Acid |
Bacterial Infections Opportunistic Infections Sexually Transmitted Diseases, Viral Amikacin Ofloxacin Clofazimine Streptomycin Vitamin B 6 Rifampin Gram-Positive Bacterial Infections Respiratory Tract Diseases Respiratory Tract Infections Tuberculosis, pulmonary AIDS-Related Opportunistic Infections Tuberculosis |
Capreomycin Sulfate Retroviridae Infections Isoniazid Cycloserine Ethionamide Acquired Immunodeficiency Syndrome Pyrazinamide Immunologic Deficiency Syndromes Virus Diseases HIV Infections P-Aminosalicylic Acid Lung Diseases Sexually Transmitted Diseases Tuberculosis, Pulmonary Mycobacterium Infections |
Antimetabolites Anti-Inflammatory Agents Anti-Infective Agents Slow Virus Diseases Molecular Mechanisms of Pharmacological Action Physiological Effects of Drugs Renal Agents Infection Anti-Bacterial Agents Sensory System Agents Vitamins Therapeutic Uses Anti-Inflammatory Agents, Non-Steroidal Micronutrients Analgesics |
Nucleic Acid Synthesis Inhibitors RNA Virus Infections Vitamin B Complex Immune System Diseases Growth Substances Antilipemic Agents Anti-Infective Agents, Urinary Enzyme Inhibitors Pharmacologic Actions Actinomycetales Infections Antibiotics, Antitubercular Protein Synthesis Inhibitors Analgesics, Non-Narcotic Lentivirus Infections Antitubercular Agents |